NCT04819464View on ClinicalTrials.gov

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 25, 2021

Primary Completion Date

August 18, 2024

Study Completion Date

August 18, 2024

Conditions

HealthyHepatic Impairment

Interventions

DRUG

Cenerimod

A single oral dose of 0.5 mg.

Trial Locations (2)

H2143

CRU Hungary, Kistarcsa

4250-449

BlueClinical Phase 1 Hospital de Prelado, Porto

All Listed Sponsors

lead

Viatris Innovation GmbH

INDUSTRY

NCT04819464 - A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod | Biotech Hunter | Biotech Hunter